We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Urology

Expert Opinion / Commentary · December 11, 2021

2021 Top Story in Urology: Taking Another Look at Clorpactin and Cyclosporine

Written by
Philip M. Hanno MD, MPH


Additional Info

  1. Mertz JH, Nourse MH, WISHARD WN,. Use of clorpactin WCS 90 for relief of symptoms due to interstitial cystitis. Trans Am Assoc Genitourin Surg. 1956;48:86-89.

  2. Wishard W, Nourse MH, Mertz JH. Use of clorpactin WCS 90 for relief of symptoms due to interstitial cystitis. J Urol. 1957;77(3):420-423.

  3. Murnaghan GF, Saalfeld J, Farnsworth RH. Interstitial cystitis – treatment with chlorpactin WCS 90. Br J Urol. 1970, Dec;42(6):744.

  4. Messing EM, Stamey TA. Interstitial cystitis: Early diagnosis, pathology, and treatment. Urology. 1978;12(4):381-392.

  5. Cvach K, Rosamilia A, Dwyer P, et al. Efficacy of clorpactin in refractory bladder pain syndrome/interstitial cystitis: A randomized controlled trial. Int Urogynecol J. 2021;32(5):1177-1183.
  6. Messing EM, Freiha FS. Complication of clorpactin WCS90 therapy for interstitial cystitis. Urology. 1979;13(4):389-392.
  7. Forsell T, Ruutu M, Isoniemi H, et al. Cyclosporine in severe interstitial cystitis. J Urol. 1996;155(5):1591-1593.

  8. Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171(6 Pt 1):2138-2141.
  9. Crescenze IM, Tucky B, Li J, et al. Efficacy, side effects, and monitoring of oral cyclosporine in interstitial cystitis/bladder pain syndrome. Urology. 2017;107:49-54.
  10. Vollstedt A, Tennyson L, Turner K, et al. Evidence for early cyclosporine treatment for Hunner lesion interstitial cystitis. Female Pelvic Med Reconstr Surg. 2021, Sep 30. doi: 10.1097/SPV.0000000000001108. Online ahead of print.
  11. Di XP, Luo DY, Jin X, et al. Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: A systematic review and bayesian network meta-analysis. Int Urogynecol J. 2021;32(5):1129-1141.
  12. Khojah MI, Badeghiesh AM, Ismail S, et al. Interstitial cystitis/bladder pain syndrome's correlations with pregnancy and neonatal outcomes: A study of a population database. J Urol. 2021;206(4):978-985.
  13. Nickel JC, Doiron RC. Hunner lesion interstitial cystitis: The bad, the good, and the unknown. Eur Urol. 2020; 78(3):e122-e124.
  14. Hanno P, Fall M, Meijlink J, Nordling J. Towards a new paradigm in bladder pain syndrome and interstitial cystitis. BJU Int. 2020;126(5):549-550.
  15. Plair A, Evans RJ, Langefeld CD, et al. Anesthetic bladder capacity is a clinical biomarker for interstitial cystitis/bladder pain syndrome subtypes. Urology. 2021, Jul 22. doi: 10.1016/j.urology.2021.07.009. Online ahead of print.
  16. Lai HH, Newcomb C, Harte S, et al. Comparison of deep phenotyping features of UCPPS with and without Hunner lesion: A MAPP-II research network study. Neurourol Urodyn. 2021;40(3):810-818.

Disclosure statements are available on the authors' profiles:

Further Reading